
RESEARCHARTICLE PeroralEstradiolIsSufficient toInduce Carcinogen-Induced Mammary Tumorigenesis inOvariectomized Rats withoutProgesterone HillaryStires,MarianaSaboya,Samantha P.Globerman, WendieS.Cohick* DepartmentofAnimalScience,Rutgers,TheStateUniversityofNewJersey,NewBrunswick,NJ,United StatesofAmerica *cohick@aes op.rutgers.ed u Abstract Aroleforestrogensinbreastcanceriswidelyaccepted,however,recentevidencehigh- lightsthattimingandexposurelevelsareimportantindeterminingwhethertheyelicitharm- fulversusbeneficialeffects.Theratchemicalcarcinogenmodelhasbeenwidelyusedto studytheeffectsofestrogensbutconclusions onthelevelsthatleadtotumordevelopmen t andanabsoluterequirement forprogesterone (P4)arelacking.Anewermethodofhor- moneadministration mixeshormoneswithnutbutterforperoralconsumption allowingfora lessstressfulmethodoflong-termadministration withlowerspikesinserumestradiol(E2) levels.Thepresentstudywasdesignedtodetermineifestrogensaloneataphysiological dosecandrivecarcinogen-induced tumorsinovariectomize d(OVX)ratsorifP4isalso requiredusingthismethodofhormoneadministration.
Short-termstudieswereconducted todeterminethedoseofestrogen(E)thatwouldleadtoincreaseduterineweightfollowing OVX.Subsequently ,ratswereOVXonpostnatalday(PND)40thentreateddailywithE (600μg/kg/day),P4(15mg/kg/day),orthecombination. OnPND50,allratswereinjected withnitrosomethylur eatoinducemammarytumors.Uterineweights,bodyweights,and serumE2levelsweremeasuredtodemonstrate theefficacyofthemethodforincreasing E2levelsduringlong-termtreatment.After26weeks,tumorincidencewassimilarinSham, E,andE+P4animalsindicatingthatEwassufficienttoinducetumorigenesis whenhor- monelevelswerenormalizedbythismethod.Thisstudydemonstrates peroraladministra- tioncanbeusedinlong-termstudiestoelucidaterelationships betweendifferenttypesand levelsofsteroidhormones.Introduction Elucidatingtheroleoffemalesexsteroidsincarcinogenesis iscriticalforgeneralpreventive healthcareinwomenaswellasforunderstanding thebasicpathophysiology ofbreastcancer.
PLOSONE|DOI:10.1371/journal.pone.0162662 September9,2016 1/17a11111 OPEN ACCESS Citation: Stires H, Saboya M, Globerman SP ,Cohick WS (2016) Peroral Estradiol IsSuffi cient to Induce Carcinogen- Induced Mammary Tumorigenesis in Ovariectomiz ed Rats without Progestero ne. PLoS ONE 11(9): e0162662.doi:10.1371 /journal.pone.01626 62 Editor: Tif fany Seagroves ,University of Tennessee Health Science Center ,UNITED ST ATES Received: January 7, 2016 Accepted: August 28, 2016 Published: Septemb er 9, 2016 Copyright: ©2016 Stires et al.This isan open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproducti on inany medium, provided the original author and source are credited.Data Availabilit yStatement: All relevant data are within the paper .Funding: The authors received no specific funding for this work.Competing Interests: The authors have declared that no competing interests exist.
Itiswidely-accepted thatincreasedexposuretoestrogenoverawoman’slifespanincreasesher riskofbreastcancer[1].Aspecificroleforestrogensinthedevelopment ofluminalbreastcan- cerisdemonstrated bythefindingthattreatmentofintactratswithtamoxifenoraromatase inhibitors(AIs)beforenitrosomethylurea (NMU)or7,12-dimethylbenz (a)anthracene (DMBA)administration attenuatescarcinogen-induced tumordevelopment [2,3].However, howmoderatefluctuationsincirculatingestrogenlevelswithinanormalphysiological range influencecancerincidenceisnotwellunderstood.Avarietyofmethodsareusedtoadminister steroidsinovariectomized (OVX)rodentsincludingsilastictubing,hormonepellets,anddaily subcutaneous injections.Thesemethodsinitiallyresultinsupraphysiological levelsofhormone [4]whichmaybeaconfounding factorsinceshort-termexposuretohighlevelsofestrogens canpreventtumordevelopment [5].Introducinghormonesperorallyinnutbutterisanewer methodofhormonedeliverythatislessstressfulthanoralgavageorinjectionsandleadsto morenormalizedlevelsofovarianhormonesfollowingovariectomy, withoutaninitialsupra- physiological spikeinbloodconcentrations [4].Thismethodalsohastheadvantagethatit mimicsoraladministration ofhormonereplacementtherapy(HRT),themostcommon methodofdeliveryinwomen.Oraladministration requireshigherdosesofsteroidstoelevate systemiclevelsduetoextensivemetabolismbythegutandliver,whichcanalsoresultinadif- ferentmetabolicprofilefromthatofotherroutesofadministration [6,7].However,toour knowledge,peroraladministration hasnotyetbeenusedinrodentstudiestostudytheroleof estrogenincarcinogen-induced tumordevelopment.
Similartoestrogens,progesterone (P4)issecretedfromtheovary,cyclesoverawoman’s lifespananddecreasesinmenopause.WhetherP4playsaroleincarcinogen-induced tumori- genesishasnotbeenstudiedasextensivelyasestrogens.TheintactACIratspontaneously developstumorsinresponsetohighdosesofestrogensbuthighconcentrations ofbothestro- gensandP4arerequiredfortheresponseinOVXanimals[8].TheimportanceofP4inother studiesusingOVXrodentsisunclear[9,10].Aswithestrogen,divergentresultsmaybedueto boththemodeofadministration andtheserumconcentrations obtainedwithdifferent methods.
Giventhatperoralhormoneadministration representsaless-stressful methodofhormone administration thatresultsinmorephysiological levelsofestrogenandmimicsoralHRT,the overallgoalofthisstudywastodetermineitsusefulnessforlong-termcarcinogenstudies.A specificgoalofthestudywastodetermineifestradiol(E2)alonecanrestorecarcinogen- inducedtumorigenesis orifP4isalsorequiredwiththismethod.Short-termstudieswerecon- ductedtodeterminetheoraldoseofE2thatwasestrogenic,whichwasthenusedforalong- termstudy.Resultsindicatedthatlong-termperoralhormonereplacementfollowingOVX leadstophysiological levelsofE2thataresufficienttorestoretumorigenesis inresponseto NMUwithoutP4.
MaterialsandMethods AllanimalprocedureswereapprovedbytheRutgersUniversityInstitutionalAnimalCareand UseCommitteeaccordingtoNIHguidelines.Allsurgerywasperformedunderisofluranegas andalleffortsweremadetominimizesuffering.Duringsurgery,animalsweregivenBupiva- caine(HenrySchein;Dublin,OH)asalocalanesthetic.Post-operative careincludedlocal administration ofBuprenex(HenrySchein)asalocalanalgesicfollowedbydailymonitoring fortwoweeks.Fortumordevelopment studies,animalsweresacrificediftheirtumorvolume (asmeasuredbyS2L/2whereSandLaretheshortestandlongestdiameterinmm,respec- tively)exceeded10%ofbodyweightorthemeantumordiameterexceeded40mm.
EffectsofPeroralHormonesonCarcinogen-In ducedMammaryTumorigenesis PLOSONE|DOI:10.1371/journal.pone.0162662 September9,2016 2/17 PreparationandAdministration ofHormones E2,E2benzoate(EB),andP4(Sigma-Aldrich; St.Louis,MO)wereindependently dissolved inethanolpriortodissolutioninsesameoil(Sigma-Aldrich) ataconcentration of600μg/ml (E2orEB)and15mg/ml(P4).Equivalentvolumesofethanolwithouthormonewereadded tosesameoiltoserveasthevehiclecontrolforeachhormone.Bodyweightswereobtained priortofeedingeachdayandusedtodeterminetheappropriatevolumeofhormoneto administertoeachanimal.Eachdaytheappropriatevolumeofhormoneorvehiclewas mixedintoapproximately 4gofpeanutbutter(SkippyNaturalPeanutButter)placedon2x2 inchsquaresofparchmentpaper.Eachanimalwasofferedtwoallotmentsofpeanutbutterto achievetheappropriatetreatmentcombination e.g.E2andvehicle,P4andvehicle,E2andP4, orvehicleandvehicle.Theanimalshadaccesstothetreatmentuntilthenextdaywhenold paperswereremovedandnewtreatmentsweregiven.Hormoneconsumption wasevaluated eachmorningbeforeadministering newtreatmentsbasedonvisualization ofwhetherthe paperwascompletelydevoidofpeanutbutter(all),peanutbutterwaspartiallyconsumed (partial),orappearedthesameasithadwhenhormoneswereintroducedthepreviousday (none).
PilotStudiestoDetermineDoseofEB FemaleSpragueDawleyrats(CharlesRiver;Wilmington, MA)arrivedonpost-natalday (PND)28andwerehousedinacontrolledenvironment withadlibitumaccesstofood(Purina MillsLabDiet;StLouis,MO)andwater.Toacclimateanimalstothepeanutbutter,ratswere offeredpeanutbutterwithouttreatment2hoursafterlightsoneachmorningbeginningon PND35.Groupswerenormalizedbybodyweightpriortosurgeries,whichwereperformedon PND40or41.Bilateralovariectomy(OVX)orshamsurgerywascarriedoutunderisoflurane gas.Surgicalprocedureswereperformedusingtheasepticno-touchtechnique.Hormonetreat- mentswerestartedthedayaftersurgery.Sincethehalf-lifeofE2inserumisonly2to8hours [11,12],EBwaschosenduetoitslongerhalf-life.Forthefirstpilotstudy,OVXratswere dividedintothreetreatmentgroups(n=4):1)EB(150μg/kg/day);2)EB+P4(15mg/kg/day); and3)vehicle.Afourthgroupwasgivenvehiclefollowingshamsurgery(n=4).Inthesecond pilotstudy,OVXratsweredividedinto3treatmentgroups:1)EB(300μg/kg/day;n=5);2)EB (600μg/kg/day;n=5);and3)vehicle(n=3)withafourthgroupthatreceivedvehiclefollow- ingshamsurgery(n=3).After10daysoftreatment,ratsweresacrificedbyrapiddecapitation.
Theuteriwereexcisedanddefattedthenweighed.Forshamanimals,ovarieswereremoved fromtheuterinehornspriortoweighing. NMUTumorStudy RatsarrivedfromCharlesRiveronPND28andwerehousedandmaintainedasdescribed above.GroupswerenormalizedbybodyweightonthedayofsurgeryperformedonPND40 or41.OVXratsweresubsequently treatedwithEB(600μg/kg/day;n=8),P4(15mg/kg/day; n=7);EB+P4(n=8);orvehiclealone(OVX;n=8)startingthedayaftersurgery.A5th groupwasgivenvehiclefollowingshamsurgery(Sham;n=8).OnPND50,ratswereinjected I.P.with50mg/kgNMU(Sigma-Aldrich).Allinjectionswerecompletedwithinonehour ofdissolvingNMUinsterile0.9%saline(pH4).Ratswerepalpatedfortumorsbiweekly starting4weekspost-NMUinjectionandmeasuredusingaVerniercaliper.Tumorvolume wasmeasuredandcalculatedasdescribedabove.Bodyweightswererecordedbiweekly.
Ratchowwaskeptinhoppersforthedurationofthestudytomonitorfoodconsumption biweekly.Bloodwastakenfromthelateraltailvein4,8,and12weeksafterNMUinjection3 to5hoursafterhormoneswereoffered.Severalanimalsweresacrificedearlybecausetheir EffectsofPeroralHormonesonCarcinogen-In ducedMammaryTumorigenesis PLOSONE|DOI:10.1371/journal.pone.0162662 September9,2016 3/17 tumorvolumesexceeded10%oftheirbodyweight.Thisincludedtworatsfromthegroup treatedwithEB/E2(E)(sacrificed13and25weekspostNMU),oneratfromtheE+P4 group(sacrificed24weekspostNMU)andoneratfromtheShamgroup(sacrificed16weeks postNMU).Remainingratsweresacrificedbyrapiddecapitation twenty-sixweeksafter NMUinjection.Tumorswereexcisedandstoredin10%neutralbufferedformalin(NBF). Peltswereremovedthenstretched,pinnedtoawoodenboard,andsubmergedin10%NBF.Uteriwereexcised,fatwasremoved,anduteriwereweighed.ForShamanimals,ovarieswere removedfromtheuterinehornspriortoweighing.Imagesoftheuteriweretakenpriorto storagein10%NBF.
SerumE2Levels Bloodtakenfromthelateraltailveinwasallowedtoclotfor30minutesatroomtemperature thenspunat1500xgfor10minutesat4°C.Serumwascollectedandstoredat-80°Cuntilfur- theranalysis.E2levelsweredeterminedusinganELISAfollowingthemanufacturer’s direc- tions(Calbiotech;SpringValley,CA).AllsamplesfromtheEonlyandE+P4groupswere analyzed,whileasubsetofShamanimalswereincludedforcomparison.ForOVXanimals, serafromindividualanimalswerecombinedtogeneratefourpoolsforanalysis. MammaryGlandWholeMountAnalysis Afterfixingpeltsin10%NBFforatleast10days,theleftfourthinguinalmammaryglandwas dissectedawayfromtheskin,stretchedonslides,andallowedtoair-dryfor30min.Ifthis glandcontainedatumor,thecontralateral glandwasusedforanalysis.Glandswerethenrehy- dratedin70%,50%,and25%ethanol,placedinH2Ofor5min,andstainedincarminealum for1–2days(Sigma-Aldrich).
Afterstaining,slidesweredehydratedin70%and95%ethanol followedbyxylene.Glandswereclearedintoluenefor1–6weeksafterdehydrationtoremove excessfatthenairdriedfor30minutesbeforemountinginSealPAKpouches(Kapak;Minne- apolis,MN)withcedarwoodoil(Acros;Geel,Belgium).Wholemountswereimagedusinga NikonDS-Fi1camera(Nikon;Melville,NY)withNISElementssoftware(Nikon).Thelength ofthemammaryparenchymawasmeasuredusingthestraightlinefunctioninFIJIIsJustIma- geJ(FIJI)[13]fromthefaredgeofthelymphnodetothemostdistalpointoftheductalstruc- tureofthegland.Toenhancemagnification, glandswereviewedandimagestakenusinga LeicaMDG41stereomicroscope (Leica;BuffaloGrove,IL). TissueHistology Fixedtumoranduterinetissuesweredehydrated,cleared,andembeddedinParaplastusing facilitieslocatedintheHistopathology CoreoftheEnvironmental Occupational HealthSci- encesInstituteatRutgersUniversity.Samplesweresectionedat6μmandplacedonslides.
Foruteri,crosssectionswereobtained.Slideswerebakedfor15minutesat60°C,followedby deparafinization inxyleneandrehydrationindecreasingconcentrations ofethanol.Slides werestainedwithhematoxylin andeosinthenmountedwithPermount.Atoxicological pathologist,whowasblindtotreatment,viewedtumorslidestodeterminewhetherthe tumorswereadenomasoradenocarcinomas basedonthemostmalignantportionofeach tumorfollowingpreviouslydefinedcriteria[14].Uteriwerescoredtoquantitatethegrade (0–3)andstage(0–3)ofmetaplasia,whichwereaddedtogethertoobtainanoverallscore. Representative imagesof0+0,1+1,2+2,and3+3weretakenusinganOlympusFSX100 microscope(Olympus;Waltham,MA).
EffectsofPeroralHormonesonCarcinogen-In ducedMammaryTumorigenesis PLOSONE|DOI:10.1371/journal.pone.0162662 September9,2016 4/17 Immunohistochem istry(IHC) Fixedtumortissuewasdehydrated,cleared,andembeddedasdescribedabove.Slideswerebaked at55°Cfor30minutes,deparaffinized inxylene,andrehydratedindecreasingconcentrations of ethanol.Antigenretrievalwasperformedbyboilingslidesin0.01Msodiumcitratebufferfor30 minutesthencooledatroomtemperatureto45°Cbeforeproceeding. ForKi67,tissueswereblockedinnormaldonkeyserum(SantaCruzBiotechnology; Dallas, TX)for30minutesatroomtemperature.
Sampleswereincubatedovernightat4°Cwitheither rabbit-Ki67primaryantibody(1:100,ab16667;Abcam;Cambridge,MA)orrabbitprimary antibodyisotypecontrol(LifeTechnologies; GrandIsland,NY),whichservedasanegative controloneachslide.ThefollowingdaythetissueswereincubatedwithAlexafluor488labeled donkeyanti-rabbitsecondaryantibody(LifeTechnologies) for60minutesatroomtempera- ture.Slideswerecounterstained withDAPI(LifeTechnologies) thenmountedwithProlong GoldAntifade(LifeTechnologies). Forestrogenreceptor α(ERα)andP4receptor(PR),endogenousperoxidaseactivitywas blockedusing3%H2O2for10minutes.ERαsectionswereblockedwithnormalgoatserum (VectorLaboratories; Burlingame,CA)followingthemanufacturer’s directionswhilePRwas blockedwithnormalhorseserum(VectorLaboratories) ina1:1dilution.RabbitERαprimary antibody(MC20;SantaCruzBiotechnology) wasdilutedin1%BSAto1:500whileMousePR primaryantibody(MS-197-P0; ThermoScientific) wasdilutedinPBS+0.1%tritonto1:300.
RabbitandmouseprimaryantibodyisotypecontrolservedasnegativecontrolsforERαand PR,respectively.Secondaryantibodieswereappliedaccordingtomanufacturer’s directionsfol- lowedbydevelopment in3,3'-diaminobenzidine (Sigma-Aldrich). Slideswerecounterstained withhematoxylin, dehydratedwithincreasingconcentrations ofethanolfollowedbyxylenes, thenmountedusingPermount.ForallIHC,tumorsectionswereviewedandfiverepresentative picturesweretakenatran- domfromonesectionpertumorusinganOlympusFSX100microscopeat20Xmagnification.Ki67picturesweretakenwiththesameexposuresettingsforallsamplesusinggreenandblue fluorescencechannelstovisualizeantibodystainingandnucleilocation,respectively.ForERα andPR,picturesweretakenusingbrightfieldsetting.
TheamountofKi67stainingpernucleiwascalculatedusingpreviouslydescribedmethods [15].ERαandPRwereanalyzedusingthecolordeconvolution plug-inof[13].Briefly,images weresplitintobrownandpurpleimagesusingtheHDABvector.Meangreydensitywasdeter- minedfromthebrownimagethenconvertedtoopticaldensityusingtheequationOD=log (255/meangreydensity),where255isthemaximumintensityfor8-bitimages.ODvalues fromthe5separateimagespertumorwereaveragedtogiveatumorOD.Foranimalswith multipletumors,Ki67stainingorERαandPRODvaluesforalloftheirtumorswereaveraged. StatisticalAnalysis BodyweightswereanalyzedusingarepeatedmeasuresANOVAfollowedbyaposthocBon- ferroni-Dunn multiplecomparisonteststhrough13weekswhenthefirstratwassacrificed.
Bodyweightswerealsoanalyzedonthefinaldayofthestudybyone-wayANOVAwithNew- man-Keulsposthocanalysis.Uterineweights,tumorburden,andmammaryglandlengthwere analyzedusingaone-wayANOVAwithNewman-Keuls posthocanalysis.Tumorincidence wasanalyzedusingaMantel-CoxLog-ranktest.TumortypewasanalyzedusingaChi-square analysis.Uterinescore,Ki67expression,ERαexpression,andPRexpressionwereanalyzed usingaKruskal-Wallis testwithDunn’sMultipleComparisons posttestoraMannWhitney test.GraphPadPrismversion5.0(LaJolla,CA)wasusedtoperformstatisticalanalysesand p0.05wasconsideredsignificant.
EffectsofPeroralHormonesonCarcinogen-In ducedMammaryTumorigenesis PLOSONE|DOI:10.1371/journal.pone.0162662 September9,2016 5/17 Results Short-termStudies TodeterminethedoseofperoralEBthatwouldrestoreE2tophysiological levelsinOVXani- mals,twoshort-termstudieswereconductedusinguterineweightsasameasureofestrogeni- city.Asexpected,uterineweightsintheOVXgroupwerelessthanthoseintheshamgroupten daysaftersurgeryinbothstudies.Inthefirststudy,150μg/kg/dayEBaloneorincombination with15mg/kg/dayP4wasunabletorestoreuterineweightsoverOVX(Fig1a).Inthesecond study,dailytreatmentwith300μg/kgEBperorallywasunabletorescuethedecreaseinuterine weightcausedbyOVX,whilethe600μg/kgdoseincreaseduterineweightoverOVX(p<0.05; Fig1b).Therefore,the600μg/kgdailydosewaschosenforthelong-termtumorstudy. Long-termNMUStudy Hormone Consumption.
RatswereOVXonPND40andtreateddailywithhormones until26weekspostNMUinjection.Hormoneconsumption overthefirstfiveweeksofthe studyrevealedthatanimalstreatedwithEB(eitheraloneorincombination withP4)consumed “partial”or“none”ofbothoftheirtreatmentswhileanimalstreatedwithvehiclealoneorwith P4lickedtheirpaperscleaneachday.Theobservationthatanimalsconsumedtheentire Fig1.ThemosteffectivedoseofEBforperoraladministrationfollowingOVXis600μg/kg/day.Uteri wereexcisedanduterinewetweightsweredeterminedatsacrifice(forShamanimals,ovarieswereremoved priortoweighing).Uterineweightsareexpressedasmean±SEM,p<0.05,one-wayANOVA;Newman- Keul’sposttest;differentlettersdenotesignificantdifference.(a)Inthefirstshort-termstudy,uterineweights ofhormone-treatedratswerenotdifferentfromOVX(n=4).(b)Inthesecondstudy,600μg/kg/dayEB increaseduterineweightoverOVX(n=5,3,and3forEBtreated,Sham,andOVXanimalsrespectively).
doi:10.137 1/journal.pone.01 62662.g 001 EffectsofPeroralHormonesonCarcinogen-In ducedMammaryTumorigenesis PLOSONE|DOI:10.1371/journal.pone.0162662 September9,2016 6/17 vehicleorP4treatmentssuggestedthattheanimalshadatasteaversiontoeithertheE2orben- zoatecomponent[16]oftheEB.Therefore,animalstreatedwithEBwereswitchedtoE2start- ing4weekspostNMU.Thischangedidnotseemtocorrecttheproblemasanimalstreated withE2+vehicleorE2+P4continuedtoconsumepartialhormonefortheremainderofthe study.
Uterine andBodyWeights.UterifromShamanimalsandanimalstreatedwithEorE +P4appearednormalandweresimilaruponvisualinspection.UterifromOVXanimals treatedwithorwithoutP4wereatrophiedandvisuallyindistinguishable fromeachother(Fig 2a).Asexpected,uterineweightsweresignificantlydecreasedinOVXcomparedtoShamani- mals(Fig2b).TreatmentwithEorE+P4increaseduterineweightsoverOVXwhiletreatment withP4alonedidnotaffectuterineweight(p<0.05;Fig2b).BodyweightsofOVXandP4 onlygroupsweredifferentfromthoseofShambeginningat4and7weekspostNMUinjection, respectively(p<0.01),whilethoseofEonlyandE+P4werenotdifferentfromShamcontrols through13weekspost-NMUinjectionwhenthefirstanimal(offourtotal)neededtobesacri- ficedearlyduetolargetumorsize(p<0.05;Fig2c).
SerumE2.TomonitorserumE2levels,bloodwascollectedfromratsviathelateraltail veinfromallanimalsbeginningeither3or5hoursafterhormoneswereadministered at4,8 Fig2.Long-termdailyperoralEtreatment isphysiologicallyactive.Atsacrifice,uteriwereexcisedand weighed.Imagesofuteriweretakenbeforestoragein10%NBF.(a)Representativeimagesofuterifrom eachtreatmentgroup.(b)UterineweightswerereducedinOVXratstreatedwithvehiclebutincreasedwithE orE+P4treatment.P4alonewasunabletorestoreuterineweights.Uterineweightsareexpressedas mean±SEM;n=8,7forP4only;p<0.05,one-wayANOVA;Newman-Keul’sposttest;differentletters denotesignificantdifference.(c)Ratswereweighedbiweeklyforthedurationofthestudy.Long-term exposuretoEorE+P4resultedinbodyweightsthatweresimilartothoseofShamcontrols.Dailytreatment withP4didnotpreventweightgainfollowingOVX.Bodyweightsareexpressedasmean±SEM,n=8,7for P4only;repeatedmeasuresANOVAthroughthefirstanimalsacrificeat13weekspostNMU(PND148) (treatment:p<0.01)withBonferroni-Du nnmultiplecomparisonstest(*startofp<0.05forOVX,#startof p<0.05forP4only;comparedtoSham).Thepatternpersistedintheremaininganimalsattheendofthe study(p<0.05,one-wayANOVA,Newman-Keul’sposttest).
doi:10.137 1/journal.pone.01 62662.g 002 EffectsofPeroralHormonesonCarcinogen-In ducedMammaryTumorigenesis PLOSONE|DOI:10.1371/journal.pone.0162662 September9,2016 7/17 and12weekspost-NMUinjection.SerumfromEonlyandE+P4groupswasanalyzedatall timepointswhileasubsetofsamplesfromShamanimalsandserumpoolsfromOVXanimals wereassayedforcomparison.TheinterquartilerangeofE2levelsofShamandOVXwere3.5 to14.2pg/mland3.6to7.0pg/ml,respectively.TheinterquartilerangeofserumE2levelsfor theEonlygroupwas17.2to61.4pg/mland14.5to60.8pg/mlfortheE+P4group(Fig3).
Uterine Histology.SinceserumE2valuesofanimalstreatedwithEwereelevatedoverval- uesofShamcontrols,uterinemorphologywasanalyzedtodetermineiftherewereanyabnor- malitiesinducedbyE2treatment.P4onlyandOVXanimalswerenotincludedintheanalysis sincetheiruteriwereatrophiedanddidnotdisplayanymetaplasia.Visualobservationofuterine sectionsfromEonly,E+P4,andShamanimalsrevealedepithelialmetaplasiathatwasextensive insomesamplesandlessapparentinothers.Toquantifythechanges,atoxicologicalpathologist determinedhowextensivetheinjurywas(stage)andhowdisorganizedthecellswere(grade). Representative imagesarepresentedinFig4.Stageandgradewereaddedtogethertogivean overalluterinescoreandscoreswerecompiledbygroup.Therewasmoreextensiveuterinemeta- plasiaintheEonlygroupcomparedtoSham(p<0.05).ThemetaplasiaintheE+P4group tendedtobelessextensivethanintheEonlygroup,butstillmoreextensivethaninShamgroup.
Mammary Glands.SinceE2andP4areimportantfornormalmammaryglandgrowth andmaintenance, mammaryglandwholemountswerepreparedandimagedtoanalyzemor- phology.Asexpected,theductalstructuresoftheglandsintheShamgroupextendedtothe endofthefatpadswithbranchingandalveolarbudsappropriateforadultvirginanimals(Fig 5a).ThemammaryglandsofanimalstreatedwithEorE+P4appearedsimilar(Fig5band 5c).TheglandsfromtheOVXandP4groupswereindistinguishable fromoneanotherand exhibitedverythinductsandlackedalveolarbuds(Fig5dand5e).Parenchyma ofmammary glandsfromOVX±P4animalsdidnotextendasfarintothefatpadrelativetotheparen- chymaoftheShamandEorE+P4glands(Fig5fand5g). TumorDevelopment.
Todeterminetheinfluenceoflong-termperoralhormonetreat- mentonmammarytumordevelopment, ratswereinjectedwithNMUonPND50.Tumors werepalpatedbiweeklyandtumorincidencewascalculated(Fig6a).Thefirsttumorsappeared Fig3.SerumE2levelsareelevatedwithperoralhormonetreatment.Bloodsamplesweredrawnfrom thelateraltailvein5,3,and5hoursaftertreatmentswerepresented4,8,and12weeksafterNMUinjection, respectively.Blooddrawsfromallanimalswerecompletedwithin2hoursoneachofthethreedays.Serum wasanalyzedusinganE2ELISA(Calbiotech).Bloodfromoneanimalinthe12-weekEonlygroupandone animalinthe8-weekE+P4grouphemolyzed,thusthesesampleswerenotincludedintheanalysis.All valuesfromEandE+P4animalsarepresentedtodemonstratetherangeofserumE2acrossanimalsand treatmentswhileasubsetofShamanimalsandserumpoolsfromOVXanimalswereincludedfor comparison.Horizontallinesindicatemeanvaluesforeachtimepoint.
doi:10.137 1/journal.pone.01 62662.g 003 EffectsofPeroralHormonesonCarcinogen-In ducedMammaryTumorigenesis PLOSONE|DOI:10.1371/journal.pone.0162662 September9,2016 8/17 6.5weekspostNMUinjectioninEonly,E+P4,andShamgroups.Therewasnodifference betweentumorincidenceinEonly,E+P4,orShamgroups26weekspostNMUinjection.
TheretendedtobeanincreaseintumorlatencyintheEonlygroup.Onetumordevelopedin theOVXgroup8.5weekspostNMUinjection.Alltumorswereadenomasoradenocarcino- mas.Interestingly, therewasasignificantdifferenceintumortypebytreatmentgroupwithE andE+P4treatedgroupsdevelopingmoremalignanttumors(p<0.05;Fig6b).Autopsy Fig4.Treatment withEleadstoincreased uterinemetaplasia intreatedanimals.Crosssectionsofuteriwerestainedwithhematoxylin andeosin.Atoxicologicalpathologiststagedandgradedtheslidesfrom0–3foreachcategoryleadingtoscoresofstage+grade,specifically focusingontheuterinelumen(arrows)andnotondilatedducts(arrowheads).Imagesarerepresentativeof0+0(relativelynormal),1+1,2+2, and3+3respectively.Thelargerimagesweretakenat20Xmagnificationandtheinsetat4Xmagnification.Scoreswerederivedbyadding stageandgradetogetafinalscoreof0–6.P4onlyandOVXanimalswerenotincludedinanalysisasalluteriwereatrophiedandnot metaplastic.Uterinescoresareexpressedasmean±SEM;n=8;p<0.05,Kruskal-WallistestwithDunn’sMultipleComparison’sposttest; differentlettersdenotesignificantdifference.
doi:10.137 1/journal.pone. 0162662.g004 Fig5.Mammaryglanddevelopm entofEandE+P4treatedanimalsissimilartoShamcontrols.Representativeimagesofwhole mounts(4Xmagnification)demonstratedductalthicknesswassimilarinSham(a),Eonly(b),andE+P4(c)whiletheoverallmorphologyof glandswassimilarbetweenOVX(d)andP4only(e)withthinnerductsrelativetotheothergroups.Thelengthofthemammarygland parenchymawasmeasuredfromthelymphnodetothemostdistaledgeoftheductsusingFIJIasshownin(f).TheparenchymafromSham, Eonly,andE+P4glandsexhibitedsimilarductallengthswhileOVXandP4onlywereshorter(g).Mammaryglandlengthisexpressedas mean±SEM;p<0.05,one-wayANOVA;Newman-Keul’sposttest.
doi:10.137 1/journal.pone.01 62662.g 005 EffectsofPeroralHormonesonCarcinogen-In ducedMammaryTumorigenesis PLOSONE|DOI:10.1371/journal.pone.0162662 September9,2016 9/17 Fig6.Peroraltreatment withEandE+P4afterOVXresultsinsimilartumorincidencebutmore adenocarcinomas followingNMUrelativetoSham.(a)RatswereOVXonPND40,injectedwithNMUon PND50,andpalpatedbiweeklyfortheappearance oftumors.Therewasnodifferenceintumorincidence betweenE,E+P4andShambutallthreegroupsweredifferentfromPonlyandOVX,whichwerenot differentfromoneanother(p<0.05,Mantel-CoxLog-ranktest).(b)Tumortypewasclassifiedbya histologicalpathologistasadenomaoradenocarcinomabasedonthemostmalignantpartofeachsection.
TheeffectoftreatmentontumortypewasanalyzedusingaChi-squareanalysis(*p<0.05).(c)Tumorswere EffectsofPeroralHormonesonCarcinogen-In ducedMammaryTumorigenesis PLOSONE|DOI:10.1371/journal.pone.0162662 September9,2016 10/17 revealedthatthesingleOVXanimalthatpresentedwithatumorwastheonlyanimalthathad largemetastasestothelungswhichwasconfirmedbyhistologicalexamination. Totaltumor burdenwascalculatedbyaddingthevolumesofindividualtumorsforeachanimal.Therewas nodifferenceintotaltumorburdenalthoughtheEonlygrouptendedtohaveagreaterburden thantheE+P4grouportheShamgroup(Fig6c).
TumorIHC.Ki67wasanalyzedasamarkerofproliferation andERαandPRwere assessedtodeterminehormonereceptorstatus.Representative imagesoflowandhighexpres- sionlevelsforeachmarkerareshowninFig7.TherewerenosignificantdifferencesinKi67 stainingbetweentheSham,Eonly,andE+P4groups,althoughtheEonlygrouptendedtobe lower(Fig7c).Similarly,therewerenosignificantdifferencesbetweengroupsforexpressionof ERα(Fig7f).TherewasnosignificantdifferenceinPRexpressionbetweenthethreetreatmentmeasuredwithaVerniercaliperthemorningofsacrifice.Tocalculatetumorburden,thevolumeofeach tumorwasaddedtogetherperanimal.Therewerenodifferencesintumorburdenamongtreatmentgroups.
doi:10.137 1/journal.pone.01 62662.g 006 Fig7.Treatment ofOVXanimalswithEorE+P4resultsintumorswithsimilarproliferationindicesandreceptorstatusrelativeto tumorsfromShamcontrols.Ki67,ERα,andPRIHCwasperformedandmeasuredasdescribed.Imagesdepictinglow(a,d,g)andhigh (b,e,h)expressionofKi67,ERα,andPRarepresentedwithcorrespondingscoresinthebottomleftcornerofeachimage.Therewereno differencesinKi67orERαexpressionbetweentreatmentgroups.AnimalstreatedwithE+P4hadmorePRexpressionthananimals treatedwithEalone(Mann-WhitneytestcomparingEonlytoE+P4,p<0.05). doi:10.137 1/journal.pone.
0162662.g007 EffectsofPeroralHormonesonCarcinogen-In ducedMammaryTumorigenesis PLOSONE|DOI:10.1371/journal.pone.0162662 September9,2016 11/17 groups.However,comparingPRexpressionbetweenEvs.E+P4indicatedexpressionwas greaterinanimalstreatedwithE+P4comparedtothosetreatedwithEonly(MannWhitney test,p<0.05;Fig7i).ShamanimalshadPRexpressionthatfellintherangeoftheEonlyand E+P4groups.ThetumorfromtheOVXanimalhadoneofthehighestKi67expressionlevels andthelowestERαandPRexpression(datanotshown). Discussion Thegoalsofthisstudyweretwo-fold:(1)todetermineiftumorscanbeinducedusingperoral hormoneadministration aspreviouscarcinogenstudiesusedmethodsthatresultedinsupra- physiological levelsofhormoneorinducedstress[4]and(2)todetermineifestrogensalone candrivecarcinogen-induced tumorigenesis inOVXratsintheabsenceofP4usingthis methodofhormoneadministration.Peroraladministration representsastress-freemethodto administerhormonesthatmimicsoralhormoneingestion,themostcommonmethodofHRT.
Oraladministration producesahepatic‘first-pass’effect,resultinginextensivemetabolismof thehormonesaswellasstimulationofhepaticfactors[6,7,17].Thesefirst-passeffectscould potentiallyimpacttumorigenesis astheydoforcardiovascular andvenousfunction[6,7,17]. Thereforeperoraladministration providesamethodofhormonedeliverythatmimicsoral HRTintermsofboththehighdosesofsteroidsinitiallypresentedtotheliveraswellasulti- matebioavailability toothertissues.Inthecurrentstudy,bodyweightsanduterineweights followingsixmonthsofperoralhormoneadministration indicatedthathormoneswerebiolog- icallyactiveoveranextendedperiodoftime.
PilotstudieswerenecessarytoensurethedoseofEchosenwouldbesufficientlyestrogenic [18].Previousshort-termstudieswithperoraladministration usedalowerdoseofE2(28μg/ kg/day)thatwasunabletorestoreuterineweights[4].Generally,higherdosesarerequiredfor peroraladministration sincefirstpassthroughtheliverandgutdecreasesoverallbioavailability [6,19,20].Inthepresentwork,onlythe600μg/kgdoseincreaseduterineweightsoverthe OVXanimalsinashort-termten-daystudyandwasthereforeusedforthelong-termstudy. Whileperoralfeedingofnutbutterhasbeenexaminedasausefulmethodofhormone administration, thisisthefirstlong-termstudytoexamineitseffectivenessinacarcinogenic- inducedmodeloftumorigenesis.
Afteralittleoveramonthoffeeding,ratstreatedwithEB(E onlyandE+P4groups)didnotconsumealloftheirtreatmentsandwerethusswitchedtoE2 fortheremainderofthestudywiththethoughtthattheyhadatasteaversiontobenzoate,a moleculethathasbeenshowntohaveabittertaste[16].SwitchingtoE2didnothelpwithcon- sumption,whichmayhaveoccurredduetoanaversiontothetasteofE2orperhapsmore likelybecausetheanimalshadalreadydevelopedatasteaversiontoanytreatmentinpeanut butter.Interestingly, serumE2levelsdidnotcorrespondwiththepatternoffeedingthatwas observed.Itispossiblethattransdermalexposurefromthelipophilicpeanutbutterinfused withhormonesincreasedexposureoverperoralconsumption alone.Infuturestudies,itwould behelpfultodoshort-term,4-weekstudiesontasteaversionbeforebeginningalong-term study.However,basedonlong-termmeasuresofestrogenicity includinguterineweights, bodyweights,anduterinehistology,animalstreatedwithEwereexposedtosufficientlevelsof hormone.
ToensureE2levelswereelevateddespitealackofcompleteconsumption, serumE2levels weremeasuredatthreeseparatetimepoints.TheinterquartilerangeofserumlevelsinE- treatedanimalsrangedfrom17.2to61.4pg/mlintheEonlygroupand14.5to60.8pg/mlin theE+P4groupacrossthethreetimepoints.Previousstudieshaveshownthatintactanimals sacrificedduringestrusorproestrushaveserumE2levelsrangingfrom2.4to145.4pg/ml[4, 21].E2levelsinserumofShamanimalsinthecurrentstudyhadaninterquartilerangeof3.5 EffectsofPeroralHormonesonCarcinogen-In ducedMammaryTumorigenesis PLOSONE|DOI:10.1371/journal.pone.0162662 September9,2016 12/17 to14.2pg/mlwhilethoseofOVXanimalsrangedfrom3.6to7.0pg/ml.TheELISAusedinthe presentworkhasbeenreportedtobethemostaccurateandsensitivecomparedtoothercom- merciallyavailableassaysforrodentserum[22].Interestingly, similartothepresentresults, thisassaycouldnotdistinguishbetweenShamandOVXanimalsbasedonE2serumlevelsin animalsthatwerenotspecificallydeterminedtobeinproestrus[22].Therefore,whiletheval- uesreportedhereforE-treatedanimalswerehigherthanthoseofShamcontrolsinthisstudy, thelevelsweregenerallywithinaphysiological range.
SinceweeklyE2valuesrepresentedasingletimepointforeachanimal,otherendpoints wereevaluatedtobetterassessthephysiological relevanceofthedoseusedinthisstudy.OVX causesratstobecomehyperphagicandincreasespositiveenergybalanceleadingtoincreased weightgaincomparedwithshamoperatedanimals[23].TreatmentwithE2reducesbody weightgain[24–26]whileP4alonehasnoeffectonbodyweightfollowingOVX[27].Similar resultswerefoundinthepresentstudy,indicatinglong-termefficacyoftheEtreatment. Uterineweightsinthelong-termstudyfollowedthoseoftheshort-termstudywhereOVX decreaseduterineweightandtreatmentwithErescuedit.Uterinehistologywasevaluatedasa moresensitivemarkerofestrogenicity.UteriweresectionedandstainedwithH&Etoanalyze cellularendpointsincludingluminalepithelialheightandglandnumber[28].Thisanalysis indicatedthatuterididnothaveanormalhistologyandexhibiteddifferinglevelsofmetaplasia.
WhileuterinemetaplasiainresponsetoNMUhasbeenpreviouslydescribed[29],themeta- plasticresponsewasgreaterinOVXanimalstreatedwithEalonerelativetoShamcontrolsin thepresentstudy.Asexpected,treatmentwithE+P4tendedtodecreasethemetaplasia inducedbyEalone.TheseresultssuggestthatalowerdoseofEmighthavebeensufficiently estrogenicinalong-termstudywithoutinducinguterinemetaplasia. Inthepresentstudy,mammaryglandmorphology inOVXanimalswasmaintainedwith eitherEorE+P4treatment.Interestingly, therewasnotanobviousdifferencebetweenthe twotreatments,althoughagainalargersamplesizemayberequiredtodetectsubtlerdiffer- ences.Mammaryglandmorphology wasnotmaintainedwithP4alone,indicatingthatthere isanabsoluterequirement forestrogens.Similarresultswerereportedinarecentstudythat examinedE2±dydrogesterone (DG)usingasimilarmethodofhormoneadministration.
HistologicalanalysisofmammaryglandsrevealedthatDGdidnotreversetheatrophicmor- phologyobservedinOVXrats,however,treatmentwithE2withorwithoutDGresultedin mammaryglandssimilartothoseofshamcontrols[30].Whilethemeasurement included herewasaqualitativeoverviewofmammaryglandmorphology, theseresultsareinteresting aspreviousresearchhasindicatedthatE2isrequiredforpubertalmammaryglanddevelop- mentbutP4isalsorequiredformammaryglandmaintenance duringadulthoodinmice [31]. Aclearroleforestrogensisindicatedbystudiesshowingthattreatmentwithtamoxifenor AIsleadstotumorregression[3,32].However,thisexperimental paradigmdoesnotdetermine whetherP4isalsorequiredfortumorigenesis nordoesitconsidertheroleofthedoseortiming ofhormoneadministration.
Considerable datasupportsaproliferativeroleforP4inthenor- malmammarygland[33,34],however,itsroleinbreastcanceriscontroversial [34,35].The Women’sHealthInitiativeshowedthatconjugatedequineestrogens(CEE)andmedroxypro- gesteroneacetate(MPA;asyntheticprogestin)actsynergistically topromotebreastcancer comparedwithCEEalone[36,37],leadingtothehypothesisthatP4increasesbreastcancer risk.Subsequentstudiesfocusingonthetimingofadministration andtheeffectsofdifferent typesofprogestogens [38,39]indicatethatcertainprogestinsmayincreasebreastcancerrisk butnativeP4maynot.Theseepidemiological studieshaveincreasedrecognitionofthecom- plexitiesofP4’sroleinbreastcancerandtheneedtofurtherelucidatetheinteractionsbetween estrogenandP4.
EffectsofPeroralHormonesonCarcinogen-In ducedMammaryTumorigenesis PLOSONE|DOI:10.1371/journal.pone.0162662 September9,2016 13/17 Interestingly, fewstudieshaveusedovarianablationandhormonereplacementtoanswer thesequestionsandthosethathavebeenperformedhaveshownvaryingresults.Inthepresent study,tumorincidencewassimilarbetweenSham,EandE+Pgroups,indicatingthatcontrary topreviousresearchusingachemicalcarcinogeninanOVXratmodel[9,10],estrogensalone canfullyrestoretumorigenesis.
TumorsfailedtodevelopinresponsetoNMUwhen26–30mg ofE2wasadministered toOVXratsusingsilastictubing.Tumorsdiddevelopinanimals treatedwithestroneandtumorincidencenearlydoubledwhenP4wasalsoincluded[10].The authorsattributedthelackofaneffectofE2tothehighdosageadministered basedonreports thathighlevelsofE2andP4(similartolevelsseeninpregnancy)aroundthetimeofNMU administration preventmammarytumordevelopment inintactrats[40,41].Thereasonfor thedifferenceintumorburdenwithE2versusestronewasunresolved.Incontrasttofindings ofBigsby[10],tumorsdidforminresponsetoDMBAfollowingovarianablationandreplace- mentwithdailygavagefeedingof100,300,or900μg/kg/dayE2ordailyintravenousadminis- trationwith0.4,10or250μg/kg/dayE2;however,totaltumorburdenwasnotrestoredtothat ofshamanimals[42].Thecombination ofE2andP4wasnotexaminedinthisstudyandthere wasnorelationshipbetweenthedoseandtumorincidence[42].Thedifferencesbetweenour studyandpreviousstudiesmightbeattributedtothelevelofcirculatinghormonesachievedby treatment,whichwerenotmonitoredinpreviousstudies.Alternatively, thetimingofhormone administration couldinfluencetumordevelopment.
Specifically,silastictubingprovidesacon- stantslowreleaseofhormonewhileperoraltreatmentgivesadailypulseofhormone,which bettermimicsthecyclicfluctuationsinsteroids.Infuturestudiesitwouldbeworthwhileto comparemultipletypesofhormoneadministration tobetterunderstandhormonekineticsand theireffectsonlong-termphysiology.
Overalltumorburden,tumormultiplicity,andtumorphenotypealsodidnotdifferbetween theSham,EandE+P4groups.Differencesmaybemaskedbythesmallsamplesizewhichwas reducedevenmorebythefactthatnotallanimalsineachgroupdevelopedtumors.While grosstumorparametersdidnotdifferbetweenthesegroups,E-treatedanimalstendedtohave adelayintumoronset(i.e.latency)indicatingthatP4mayplayaroleintumorinitiationor enhancingtumorpromotion.AnimalstreatedwithEorE+P4hadmoreadenocarcinomas thantheShamgroupsuggestingtheelevatedlevelsofhormonemayincreasemalignantpoten- tialofthesetumors.Interestingly, tumorsfromtheE+P4grouptendedtohaveincreasedPR expressioncomparedtotheEonlygroup.Inthenormalmammarygland,treatmentwithP4 downregulates expressionofPR[43].However,tumorsdonotalwaysrespondtohormonesin asimilarmannerasthenormalgland.Forexample,cellsthatexpressERαandPRarelimited anddonottypicallydivide,butactinaparacrinemannertostimulatethedivisionofneighbor- ingcells[44,45].LuminalbreasttumorshaveincreasedlevelsofERαandPRandthecellsthat expressthesereceptorsalsodivide.Theswitchfromparacrinesignalingtoautocrinesignaling isanactiveareaofresearch.
Inconclusion,Etreatmentalonewasfoundtobesufficientforrestorationofcarcinogen- inducedtumorigenesis whenOVXratsweregivenreplacementhormoneperorally.Endpointsof E2efficacydemonstratetheusefulnessofthisapproachintermsofprovidingalow-stressmethod ofhormoneadministration thatcanbeusedtoachievecirculatingconcentrations ofphysiological levelsofhormones.Thismodelwillbeusefulinfuturestudiesdesignedtounderstandtheeffects ofcombinations ofprogestogens andestrogensonmammarytumordevelopment. Acknowledgment s TheauthorsthankDr.KennethReuhlforassistancewithstaginguterinemetaplasiaand RebeccaRietherandElenaReitmeyerfortheirtechnicalassistance.EffectsofPeroralHormonesonCarcinogen-In ducedMammaryTumorigenesis PLOSONE|DOI:10.1371/journal.pone.0162662 September9,2016 14/17 AuthorContributions Conceived anddesigned theexperiments: HSWSC.Performed theexperiments: HSMSSPGWSC.Analyzed thedata:HSWSC.Wrotethepaper:HSMSWSC.
References 1.Hilakivi-ClarkeL,deAssisS,WarriA.Exposurestosyntheticestrogensatdifferenttimesduringthe life,andtheireffectonbreastcancerrisk.JMammaryGlandBiolNeoplasia.2013;18(1):25–42.doi: 10.1007/s10911-013-9274-8PMID:23392570. 2.LubetRA,SteeleVE,DeCosterR,BowdenC,YouM,JulianaMM,etal.Chemopreventiveeffectsof thearomataseinhibitorvorozole(R83842)inthemethylnitrosourea-inducedmammarycancermodel.Carcinogenesis.1998;19(8):1345–51.PMID:9744527.3.GottardisMM,JordanVC.AntitumoractionsofkeoxifeneandtamoxifenintheN-nitrosomethylurea- inducedratmammarycarcinomamodel.CancerRes.1987;47(15):4020–4.PMID:3607747.4.IsakssonIM,TheodorssonA,TheodorssonE,StromJO.Methodsfor17beta-oestradioladministration torats.ScandJClinLabInvest.2011;71(7):583–92.doi:10.3109/00365513.2011.596944PMID: 21834617.
5.RajkumarL,GuzmanRC,YangJ,ThordarsonG,TalamantesF,NandiS.Short-termexposuretopreg- nancylevelsofestrogenpreventsmammarycarcinogenesis.ProcNatlAcadSciUSA.2001;98 (20):11755–9.doi:10.1073/pnas .201393798PMID:11573010. 6.KopperNW,GudemanJ,ThompsonDJ.Transdermalhormonetherapyinpostmenopausalwomen:a reviewofmetaboliceffectsanddrugdeliverytechnologies.DrugDesDevelTher.2009;2:193–202.PMID:19920906.7.StevensonJC.Typeandrouteofestrogenadministration.Climacteric.2009;12Suppl1:86–90.PMID: 19811249.8.BlankEW,WongPY,LakshmanaswamyR,GuzmanR,NandiS.Bothovarianhormonesestrogenand progesteronearenecessaryforhormonalmammarycarcinogenesisinovariectomizedACIrats.Proc NatlAcadSciUSA.2008;105(9):3527–32.doi:10.1073/pnas .0710535105PMID:18299580.9.OhiY,YoshidaH.Influenceofestrogenandprogesteroneontheinductionofmammarycarcinomasby 7,12-dimethylbenz(a)anth raceneinovariectomizedrats.VirchowsArchBCellPatholInclMolPathol.1992;62(6):365–70.PMID:1360723.
10.BigsbyRM.Synergistictumorpromotereffectsofestroneandprogesteroneinmethylnitrosourea- inducedratmammarycancer.CancerLett.2002;179(2):113–9.PMID:11888665. 11.TheodorssonA,HilkeS,RugarnO,LinghammarD,TheodorssonE.Serumconcentrationsof17beta- estradiolinovariectomizedratsduringtwotimessixweekscrossovertreatmentbydailyinjectionsin comparisonwithslow-releasepellets.ScandJClinLabInvest.2005;65(8):699–70 5.doi:10.1080/ 00365510500375206PMID:16319044.12.JaggerCJ,ChowJW,ChambersTJ.Estrogensuppressesactivationbutenhancesformationphaseof osteogenicresponsetomechanicalstimulationinratbone.JClinInvest.1996;98(10):2351–7.doi:10.1172/JCI119047PMID:8941653.13.SchindelinJ,Arganda-CarrerasI,FriseE,KaynigV,LongairM,PietzschT,etal.Fiji:anopen-source platformforbiological-imageanalysis.NatMethods.2012;9(7):676–82.doi:10.1038/nme th.2019 PMID:22743772.
14.PolancoTA,Crismale-GannC,ReuhlKR,SarkarDK,CohickWS.Fetalalcoholexposureincreases mammarytumorsusceptibilityandalterstumorphenotypeinrats.AlcoholClinExpRes.2010;34 (11):1879–87.doi:10.1111/j.153 0-0277.2010.01276.xPMID:20662802. 15.ArquésO,ChicoteI,TenbaumS,PuigI,G.PalmerH.StandardizedRelativeQuantificationofImmuno- fluorescenceTissueStaining.2012.http://dx.doi.org/10.1038 /protex.2012.008 16.BartoshukLM,RifkinB,MarksLE,HooperJE.BitternessofKclandBenzoate—Related toGeneticSta- tusforSensitivitytoPtc/Prop.ChemicalSenses.1988;13(4):517–28.doi:10.1093/chemse/13.4.51 7.WOS:A1988R17390000 2.EffectsofPeroralHormonesonCarcinogen-In ducedMammaryTumorigenesis PLOSONE|DOI:10.1371/journal.pone.0162662 September9,2016 15/17 17.GleasonCE,CarlssonCM,JohnsonS,AtwoodC,AsthanaS.Clinicalpharmacologyanddifferential cognitiveefficacyofestrogenpreparations .AnnNYAcadSci.2005;1052:93–115.doi:10.1196/ annals.1347.007PMID:16024754.
18.KupferD.Criticalevaluationofmethodsfordetectionandassessmentofestrogeniccompoundsin mammals:strengthsandlimitationsforapplicationtoriskassessment.ReprodToxicol.1987;1 (2):147–53.PMID:2980373. 19.O'ConnellMB.Pharmacokineticandpharmacologicvariationbetweendifferentestrogenproducts.J ClinPharmacol.1995;35(9Suppl):18S–24S.PMID:8530713.20.LongcopeC,GorbachS,GoldinB,WoodsM,DwyerJ,WarramJ.Themetabolismofestradiol;oral comparedtointravenousadministration.JSteroidBiochem.1985;23(6A):1065–70.PMID:4094413.21.StromJO,TheodorssonE,Theodorsson A.Orderofmagnitudedifferencesbetweenmethodsformain- tainingphysiological17beta-oestradiolconcentrationsinovariectomizedrats.ScandJClinLabInvest.2008;68(8):814–22.doi:10.1080/003 65510802409703PMID:18821130.22.HaisenlederDJ,SchoenfelderAH,MarcinkoES,GeddisLM,MarshallJC.Estimationofestradiolin mouseserumsamples:evaluationofcommercialestradiolimmunoassay s.Endocrinology.2011;152 (11):4443–7.doi:10.1210/en.2011-1501PMID:21933867.
23.WitteMM,ResuehrD,ChandlerAR,MehleAK,OvertonJM.Femalemiceandratsexhibitspecies-spe- cificmetabolicandbehavioralresponsestoovariectomy.GenCompEndocrinol.2010;166(3):520–8. doi:10.1016/j.ygcen.2010.01 .006PMID:20067798.24.ChanM,ChowC,HamsonDK,LieblichSE,GaleaLA.Effectsofchronicoestradiol,progesteroneand medroxyprog esteroneacetateonhippocampalneurogenesi sandadrenalmassinadultfemalerats.J Neuroendocrinol.2014;26(6):386–99.doi:10.1111/jne.12159PMID:24750490.25.SchwartzSM,WadeGN.Effectsofestradiolandprogesteroneonfoodintake,bodyweight,andcar- cassadiposityinweanlingrats.AmJPhysiol.1981;240(5):E499 –503.PMID:7235006.26.WadeGN.Someeffectsofovarianhormonesonfoodintakeandbodyweightinfemalerats.JComp PhysiolPsychol.1975;88(1):183–93 .PMID:1120795.27.WadeGN.Gonadalhormonesandbehavioralregulationofbodyweight.PhysiolBehav.1972;8 (3):523–34.PMID:4556652.
28.NewboldRR,JeffersonWN,Padilla-Bank sE,WalkerVR,PenaDS,DevelopmentalEndocrinology StudiesG.Cellresponseendpointsenhancesensitivityoftheimmaturemouseuterotropicassay. ReprodToxicol.2001;15(3):245–52.PMID:11390168.29.VerdealK,RoseDP,ErturkE,HarbergJ.Inductionofmammarytumors,estrouscycleabnormalities andendometrialhyperplasiainratsexposedtodifferentdosesofN-nitrosomethylurea.EurJCancer ClinOncol.1982;18(11):1171– 80.PMID:6891656.30.LiuJ,LinH,HuangY,LiuY,WangB,SuF.Cognitiveeffectsoflong-termdydrogesteronetreatment usedaloneorwithestrogenonratmenopausal-modelsofdifferentages.Neuroscience.2015.doi:10.1016/j.neuroscience.2015.01.042PMID:25637796.31.BriskenC,HessK,JeitzinerR.ProgesteroneandOverlookedEndocrinePathwaysinBreastCancer Pathogenesis.Endocrinology.2015;156(10):3442–50.doi:10.1210/en.20 15-1392PMID:26241069.32.JordanVC.Effectoftamoxifen(ICI46,474)oninitiationandgrowthofDMBA-inducedratmammary carcinomata.EurJCancer.1976;12(6):419–24 .PMID:821733.
33.BriskenC.Progesteronesignallinginbreastcancer:aneglectedhormonecomingintothelimelight. NatRevCancer.2013;13(6):385–96.doi:10.1038/nrc3518PMID:23702927.34.DiepCH,DanielAR,MauroLJ,KnutsonTP,LangeCA.Progesteroneactioninbreast,uterine,and ovariancancers.JMolEndocrinol.2015;54(2):R31–53.doi:10.1530/JME-14-0252PMID:25587053.35.MohammedH,RussellIA,StarkR,RuedaOM,HickeyTE,TarulliGA,etal.Progesteronereceptor modulatesERalphaactioninbreastcancer.Nature.2015;523(7560):313–7.doi:10.1038/ nature14583PMID:26153859.36.BeralV,MillionWomenStudyC.Breastcancerandhormone-replacementtherapyintheMillion WomenStudy.Lancet.2003;362(9382):41 9–27.PMID:12927427.37.RossouwJE,AndersonGL,PrenticeRL,LaCroixAZ,KooperbergC,StefanickML,etal.Risksand benefitsofestrogenplusprogestininhealthypostmenopausalwomen:principalresultsFromthe Women'sHealthInitiativerandomizedcontrolledtrial.JAMA.2002;288(3):321–33.PMID:12117397.
38.FournierA,BerrinoF,Clavel-ChapelonF.Unequalrisksforbreastcancerassociatedwithdifferenthor- monereplacementtherapies:resultsfromtheE3Ncohortstudy.BreastCancerResTreat.2008;107 (1):103–11.doi:10.1007/s10549-007-9523-xPMID:17333341. EffectsofPeroralHormonesonCarcinogen-In ducedMammaryTumorigenesis PLOSONE|DOI:10.1371/journal.pone.0162662 September9,2016 16/17 39.MirkinS,AmadioJM,BernickBA,PickarJH,ArcherDF.17beta-Estradiolandnaturalprogesteronefor menopausalhormonetherapy:REPLENISHphase3studydesignofacombinationcapsuleandevi- dencereview.Maturitas.2015;81(1):28–35.doi:10.1016/j.maturitas.2015.02.266PMID:25835751.40.GrubbsCJ,FarnellDR,HillDL,McDonoughKC.ChemopreventionofN-nitroso-N-methylurea-induced mammarycancersbypretreatmentwith17beta-estradiolandprogesterone.JNatlCancerInst.1985; 74(4):927–31.PMID:3857386.
41.SwansonSM,ChristovK.Estradiolandprogesteronecanpreventratmammarycancerwhenadminis- teredconcomitantlywithcarcinogenbutdonotmodifysurvivingtumorhistology,estrogenreceptor alphastatusorHa-rasmutationfrequency.AnticancerRes.2003;23(4):3207–13.PMID:12931682. 42.KerdelhueB,JoletteJ.Theinfluenceoftherouteofadministrationof17beta-estradiol,intravenous (pulsed)versusoral,uponDMBA-inducedmammarytumourdevelopmentinovariectomisedrats.BreastCancerResTreat.2002;73(1):13–22.PMID:12083627.43.AupperleeMD,HaslamSZ.Differentialhormonalregulationandfunctionofprogesteronereceptoriso- formsinnormaladultmousemammarygland.Endocrinology.2007;148(5):2290–300.PMID: 17317767 44.ClarkeRB,HowellA,PottenCS,AndersonE.Dissociation betweensteroidreceptorexpressionand cellproliferationinthehumanbreast.CancerRes.1997;57(22):4987– 91.PMID:9371488.
45.RussoJ,AoX,GrillC,RussoIH.Patternofdistributionofcellspositiveforestrogenreceptoralphaand progesteronereceptorinrelationtoproliferatingcellsinthemammarygland.BreastCancerResTreat. 1999;53(3):217–27.PMID:10369068.EffectsofPeroralHormonesonCarcinogen-In ducedMammaryTumorigenesis PLOSONE|DOI:10.1371/journal.pone.0162662 September9,2016 17/17
